Abnormal cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation
Clinical cardiac complications in oncologic patients may develop from subclinical myocardial damage. Biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and troponin T (cTnT) have been hypothesized to reflect preclinical cardiotoxicity earlier than echocardiography. The aim of this study...
Gespeichert in:
| Veröffentlicht in: | Bratislava Medical Journal 2012, Vol.113 (3), p.159-162 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 162 |
|---|---|
| container_issue | 3 |
| container_start_page | 159 |
| container_title | Bratislava Medical Journal |
| container_volume | 113 |
| creator | Roziakova, L Bojtarova, E Mistrik, M Krajcovicova, I Mladosievicova, B |
| description | Clinical cardiac complications in oncologic patients may develop from subclinical myocardial damage. Biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and troponin T (cTnT) have been hypothesized to reflect preclinical cardiotoxicity earlier than echocardiography. The aim of this study was to assess prospectively the serial values of these cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation (HSCT).
Twenty-one patients who were treated with allogeneic HSCT for acute leukemia at mean age of 32.8 years (range: 19-58) were studied. The conditioning regimen included high-dose cyclophosphamide in combination with total body irradiation (TBI) or busulphan. All patients were treated with anthracyclines earlier (median cumulative dose 250 mg/m, range: 150-580).
Cardiomarkers were measured before the preparative regimen (PR) and on days 1, 14 and 30 after HSCT. Their cardiac systolic function was assessed before PR, and 1-2 months after HSCT by echocardiography.
The differences in NT-proBNP before PR and after HSCT were statistically significant (p250 mg/m vs ≤250 mg/m) Cardiac symptoms developed in 3/21 (14.3 %) patients (Tab. 1, Fig. 3, Ref. 36). |
| doi_str_mv | 10.4149/BLL_2012_038 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_929504338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>929504338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c318t-b8606324c106f7470a9299ac97fa593ecf64f450aa91cc63ba8ea0033e6a38533</originalsourceid><addsrcrecordid>eNpNkM1LxDAQR4Mo7rp68yy5ebGaNGnaHNfFLyh40XOZZqdu3LapSYr439vFVTwNA4_Hj0fIOWfXkkt9c1uWVcp4WjFRHJA5F0IlTMjskMwZYyrRqSxm5CSEd8akyLg6JrM0lWmRq2xOtsu6d76Dlhrwa-s68Fv0gdqetjhusbNAB4gW-xho9AgR1_TTxg2FtnVv2KM1dIMdRDc4i3H6QsSOGmzbiYc-DC30cTK4_pQcNdAGPNvfBXm9v3tZPSbl88PTalkmRvAiJnWhmBKpNJypJpc5A51qDUbnDWRaoGmUbGTGADQ3RokaCgTGhEAFosiEWJDLH-_g3ceIIVadDbtB0KMbQzXpsimFKCby6oc03oXgsakGb6cEXxVn1a5u9b_uhF_sxWPd4foP_s0pvgH023dR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>929504338</pqid></control><display><type>article</type><title>Abnormal cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Roziakova, L ; Bojtarova, E ; Mistrik, M ; Krajcovicova, I ; Mladosievicova, B</creator><creatorcontrib>Roziakova, L ; Bojtarova, E ; Mistrik, M ; Krajcovicova, I ; Mladosievicova, B</creatorcontrib><description>Clinical cardiac complications in oncologic patients may develop from subclinical myocardial damage. Biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and troponin T (cTnT) have been hypothesized to reflect preclinical cardiotoxicity earlier than echocardiography. The aim of this study was to assess prospectively the serial values of these cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation (HSCT).
Twenty-one patients who were treated with allogeneic HSCT for acute leukemia at mean age of 32.8 years (range: 19-58) were studied. The conditioning regimen included high-dose cyclophosphamide in combination with total body irradiation (TBI) or busulphan. All patients were treated with anthracyclines earlier (median cumulative dose 250 mg/m, range: 150-580).
Cardiomarkers were measured before the preparative regimen (PR) and on days 1, 14 and 30 after HSCT. Their cardiac systolic function was assessed before PR, and 1-2 months after HSCT by echocardiography.
The differences in NT-proBNP before PR and after HSCT were statistically significant (p<0.001). The values of cTnT before and after HSCT were also significantly different (p=0.005). Persistent abnormalities (30 days after HSCT) of NT-proBNP levels were found in 19/21 patients (90.5 %) and of cTnT levels in 10/21 patients (47.6 %). The median cTnT concentrations were higher in patients treated with TBI than in patients without TBI (p=0.013). The median NT-proBNP values were higher in patients pretreated with higher cumulative doses of anthracyclines (>250 mg/m vs ≤250 mg/m) Cardiac symptoms developed in 3/21 (14.3 %) patients (Tab. 1, Fig. 3, Ref. 36).</description><identifier>ISSN: 0006-9248</identifier><identifier>ISSN: 1336-0345</identifier><identifier>EISSN: 1336-0345</identifier><identifier>DOI: 10.4149/BLL_2012_038</identifier><identifier>PMID: 22428765</identifier><language>eng</language><publisher>Slovakia</publisher><subject>Acute Disease ; Adult ; Biomarkers - blood ; Female ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Leukemia - therapy ; Male ; Middle Aged ; Natriuretic Peptide, Brain - blood ; Peptide Fragments - blood ; Transplantation Conditioning ; Troponin T - blood ; Young Adult</subject><ispartof>Bratislava Medical Journal, 2012, Vol.113 (3), p.159-162</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22428765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roziakova, L</creatorcontrib><creatorcontrib>Bojtarova, E</creatorcontrib><creatorcontrib>Mistrik, M</creatorcontrib><creatorcontrib>Krajcovicova, I</creatorcontrib><creatorcontrib>Mladosievicova, B</creatorcontrib><title>Abnormal cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation</title><title>Bratislava Medical Journal</title><addtitle>Bratisl Lek Listy</addtitle><description>Clinical cardiac complications in oncologic patients may develop from subclinical myocardial damage. Biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and troponin T (cTnT) have been hypothesized to reflect preclinical cardiotoxicity earlier than echocardiography. The aim of this study was to assess prospectively the serial values of these cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation (HSCT).
Twenty-one patients who were treated with allogeneic HSCT for acute leukemia at mean age of 32.8 years (range: 19-58) were studied. The conditioning regimen included high-dose cyclophosphamide in combination with total body irradiation (TBI) or busulphan. All patients were treated with anthracyclines earlier (median cumulative dose 250 mg/m, range: 150-580).
Cardiomarkers were measured before the preparative regimen (PR) and on days 1, 14 and 30 after HSCT. Their cardiac systolic function was assessed before PR, and 1-2 months after HSCT by echocardiography.
The differences in NT-proBNP before PR and after HSCT were statistically significant (p<0.001). The values of cTnT before and after HSCT were also significantly different (p=0.005). Persistent abnormalities (30 days after HSCT) of NT-proBNP levels were found in 19/21 patients (90.5 %) and of cTnT levels in 10/21 patients (47.6 %). The median cTnT concentrations were higher in patients treated with TBI than in patients without TBI (p=0.013). The median NT-proBNP values were higher in patients pretreated with higher cumulative doses of anthracyclines (>250 mg/m vs ≤250 mg/m) Cardiac symptoms developed in 3/21 (14.3 %) patients (Tab. 1, Fig. 3, Ref. 36).</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Leukemia - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Peptide Fragments - blood</subject><subject>Transplantation Conditioning</subject><subject>Troponin T - blood</subject><subject>Young Adult</subject><issn>0006-9248</issn><issn>1336-0345</issn><issn>1336-0345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkM1LxDAQR4Mo7rp68yy5ebGaNGnaHNfFLyh40XOZZqdu3LapSYr439vFVTwNA4_Hj0fIOWfXkkt9c1uWVcp4WjFRHJA5F0IlTMjskMwZYyrRqSxm5CSEd8akyLg6JrM0lWmRq2xOtsu6d76Dlhrwa-s68Fv0gdqetjhusbNAB4gW-xho9AgR1_TTxg2FtnVv2KM1dIMdRDc4i3H6QsSOGmzbiYc-DC30cTK4_pQcNdAGPNvfBXm9v3tZPSbl88PTalkmRvAiJnWhmBKpNJypJpc5A51qDUbnDWRaoGmUbGTGADQ3RokaCgTGhEAFosiEWJDLH-_g3ceIIVadDbtB0KMbQzXpsimFKCby6oc03oXgsakGb6cEXxVn1a5u9b_uhF_sxWPd4foP_s0pvgH023dR</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Roziakova, L</creator><creator>Bojtarova, E</creator><creator>Mistrik, M</creator><creator>Krajcovicova, I</creator><creator>Mladosievicova, B</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Abnormal cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation</title><author>Roziakova, L ; Bojtarova, E ; Mistrik, M ; Krajcovicova, I ; Mladosievicova, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c318t-b8606324c106f7470a9299ac97fa593ecf64f450aa91cc63ba8ea0033e6a38533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Leukemia - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Peptide Fragments - blood</topic><topic>Transplantation Conditioning</topic><topic>Troponin T - blood</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roziakova, L</creatorcontrib><creatorcontrib>Bojtarova, E</creatorcontrib><creatorcontrib>Mistrik, M</creatorcontrib><creatorcontrib>Krajcovicova, I</creatorcontrib><creatorcontrib>Mladosievicova, B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bratislava Medical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roziakova, L</au><au>Bojtarova, E</au><au>Mistrik, M</au><au>Krajcovicova, I</au><au>Mladosievicova, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abnormal cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation</atitle><jtitle>Bratislava Medical Journal</jtitle><addtitle>Bratisl Lek Listy</addtitle><date>2012</date><risdate>2012</risdate><volume>113</volume><issue>3</issue><spage>159</spage><epage>162</epage><pages>159-162</pages><issn>0006-9248</issn><issn>1336-0345</issn><eissn>1336-0345</eissn><abstract>Clinical cardiac complications in oncologic patients may develop from subclinical myocardial damage. Biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and troponin T (cTnT) have been hypothesized to reflect preclinical cardiotoxicity earlier than echocardiography. The aim of this study was to assess prospectively the serial values of these cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation (HSCT).
Twenty-one patients who were treated with allogeneic HSCT for acute leukemia at mean age of 32.8 years (range: 19-58) were studied. The conditioning regimen included high-dose cyclophosphamide in combination with total body irradiation (TBI) or busulphan. All patients were treated with anthracyclines earlier (median cumulative dose 250 mg/m, range: 150-580).
Cardiomarkers were measured before the preparative regimen (PR) and on days 1, 14 and 30 after HSCT. Their cardiac systolic function was assessed before PR, and 1-2 months after HSCT by echocardiography.
The differences in NT-proBNP before PR and after HSCT were statistically significant (p<0.001). The values of cTnT before and after HSCT were also significantly different (p=0.005). Persistent abnormalities (30 days after HSCT) of NT-proBNP levels were found in 19/21 patients (90.5 %) and of cTnT levels in 10/21 patients (47.6 %). The median cTnT concentrations were higher in patients treated with TBI than in patients without TBI (p=0.013). The median NT-proBNP values were higher in patients pretreated with higher cumulative doses of anthracyclines (>250 mg/m vs ≤250 mg/m) Cardiac symptoms developed in 3/21 (14.3 %) patients (Tab. 1, Fig. 3, Ref. 36).</abstract><cop>Slovakia</cop><pmid>22428765</pmid><doi>10.4149/BLL_2012_038</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-9248 |
| ispartof | Bratislava Medical Journal, 2012, Vol.113 (3), p.159-162 |
| issn | 0006-9248 1336-0345 1336-0345 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_929504338 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Acute Disease Adult Biomarkers - blood Female Hematopoietic Stem Cell Transplantation - adverse effects Humans Leukemia - therapy Male Middle Aged Natriuretic Peptide, Brain - blood Peptide Fragments - blood Transplantation Conditioning Troponin T - blood Young Adult |
| title | Abnormal cardiomarkers in leukemia patients treated with allogeneic hematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A29%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abnormal%20cardiomarkers%20in%20leukemia%20patients%20treated%20with%20allogeneic%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=Bratislava%20Medical%20Journal&rft.au=Roziakova,%20L&rft.date=2012&rft.volume=113&rft.issue=3&rft.spage=159&rft.epage=162&rft.pages=159-162&rft.issn=0006-9248&rft.eissn=1336-0345&rft_id=info:doi/10.4149/BLL_2012_038&rft_dat=%3Cproquest_cross%3E929504338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=929504338&rft_id=info:pmid/22428765&rfr_iscdi=true |